Article

Combined machine learning models, docking analysis, molecular dynamics and experimental validation for the rapid design of novel FLT3 inhibitors against AML

2024-12-10

Abstract excerpt

<title>Abstract</title> Acute myeloid leukemia (AML) is a malignant clonal disorder driven by the excessive proliferation of immature myeloid cells in the bone marrow and blood, often linked to Fms-like tyrosine kinase 3 (FLT3) mutations, which occur in about one-third of AML patients. While FLT3 inhibitors such as Midostaurin, Quizartinib, and Gilteritinib have demonstrated clinical efficacy, their therapeuti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dd7104f3-9bae-5836-b5ba-cbdf0ed2c0d1
DOI: 10.21203/rs.3.rs-5393379/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Combined machine learning models, docking analysis, molecular dynamics and experimental validation for the rapid design of novel FLT3 inhibitors against AMLDOI 10.21203/rs.3.rs-5393379/v1Read

Structure-Guided Discovery and Characterization of Novel FLT3 Inhibitors for Acute Myeloid Leukemia TreatmentSemantic proximity Read

Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: an in silico approachSemantic proximity Read

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Semantic proximity Read

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AMLSemantic proximity Read

Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico.Semantic proximity Read

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.Semantic proximity Read

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.Semantic proximity Read

Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.Semantic proximity Read

In silico Exploration Natural Compounds for the Discovery of Novel DNMT3A Inhibitors as Potential Therapeutic Agents for Acute Myeloid LeukemiaSemantic proximity Read

Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia.Semantic proximity Read

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Semantic proximity Read

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.Semantic proximity Read